Mesoblast Limited has received FDA Investigational New Drug (IND) clearance to initiate a registrational clinical trial for Ryoncil® (remestemcel-L-rknd) in children with Duchenne muscular dystrophy (DMD). This pivotal study aims to evaluate the safety and efficacy of Ryoncil, a mesenchymal stromal cell (MSC) therapy, in a population of approximately 15,000 affected children in the U.S. The trial will enroll 76 patients aged 5 to 9 years, comparing Ryoncil to a placebo in conjunction with standard care, with the primary endpoint focusing on time-to-stand at nine months.

The significance of this development lies in Ryoncil’s established safety profile in pediatric patients and its anti-inflammatory mechanism, which has shown promise in preclinical models for DMD. By targeting the inflammatory processes that contribute to muscle degeneration, Mesoblast aims to preserve muscle function and slow disease progression. The collaboration with Parent Project Muscular Dystrophy and the Duchenne Registry will enhance patient identification and trial awareness, crucial for recruitment and successful study execution.

This trial represents a potential paradigm shift in DMD research by introducing an MSC-based therapeutic approach that could alter disease trajectories at an early stage. If successful, it may set a precedent for the use of cellular therapies in managing not only DMD but also other inflammatory conditions, thereby influencing future drug development timelines and strategies in the field of regenerative medicine.

Source: globenewswire.com